AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow Growth
AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow Growth Yahoo Finance
Covered in this story
What has happened since
- AbbVie is up 0.0% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- RBC Capital Markets: at $289 · target $330 by Nov 2027 · Outperform via Investing.com
- Wells Fargo: at $289 · target $340 by Nov 2027 · Overweight via Investing.com
- UBS: at $276 · target $275 by Oct 2027 · Neutral via GuruFocus
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 34 stories mentioning AbbVie, the earliest published 6 Jan 2013.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.